论文部分内容阅读
目的观察强肝片联合胸腺肽α-1治疗低病毒载量慢性HBV感染者临床效果。方法 99例低病毒载量慢性乙型肝炎病毒(HBV)感染患者,随机分为治疗组(66例)与对照组(33例)。治疗组给予强肝片联合胸腺肽α-1治疗,对照组不予治疗。治疗6个月后检查谷丙转氨酶(ALT)、谷草转氨酶(AST)、乙肝病毒的脱氧核糖核酸(HBV-DNA)定量并与对照组比较。结果治疗6个月后,治疗组肝功能ALT、AST及HBV-DNA阴转与对照组比较,差异有统计学意义(P<0.05)。结论强肝片联合胸腺肽α-1治疗低病毒载量慢性HBV感染效果较好,药物不良反应少,值得推广应用。
Objective To observe the clinical effect of Qianggan Tablets combined with thymosin α-1 in the treatment of chronic HBV infection with low viral load. Methods Ninety-nine patients with low viral load of chronic hepatitis B virus infection were randomly divided into treatment group (66 cases) and control group (33 cases). The treatment group was given Qianggan Tablets combined with thymosin α-1 treatment, the control group without treatment. After 6 months of treatment, the alanine aminotransferase (ALT), aspartate aminotransferase (AST), hepatitis B virus DNA (HBV-DNA) were quantified and compared with the control group. Results After 6 months treatment, the liver function ALT, AST and HBV-DNA in the treatment group were significantly lower than those in the control group (P <0.05). Conclusions Qianggan Tablets combined with thymosin α-1 is effective in treating chronic HBV infection with low viral load and has few side effects. It is worth popularizing and applying.